Veracyte

Yahoo Finance • 23 days ago

Veracyte (VCYT) Turns Profitable, But Significant $27M Loss Challenges Bullish Narratives

Veracyte (VCYT) recently moved into profitability, with its net profit margin turning positive even as a significant, non-recurring loss of $27.0 million affected the latest twelve-month results to September 30, 2025. Over the past five ye... Full story

Yahoo Finance • 24 days ago

After-Hours Gainers: VCYT, RIGL, NPCE, CDNA, And FBLG Post Notable Moves Following Q3 Results

(RTTNews) - Several healthcare and biotech names posted strong after-hours gains on Tuesday following the release of third-quarter earnings and updated guidance for the remainder of 2025. The session was marked by sharp price movements as... Full story

Yahoo Finance • 24 days ago

Veracyte raises 2025 revenue outlook to $510M while accelerating double-digit growth investments

Earnings Call Insights: Veracyte, Inc. (VCYT) Q3 2025 MANAGEMENT VIEW * Marc Stapley, CEO, highlighted "another outstanding quarter" with core testing business revenue up 18% year-over-year after adjusting for Envisia, supported by 26%... Full story

Yahoo Finance • last month

Do You Believe in the Upside Potential of Veracyte (VCYT)

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued their strength in the third quarter, e... Full story

Yahoo Finance • 4 months ago

Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential

Veracyte Inc (NASDAQ:VCYT [https://www.chartmill.com/stock/quote/VCYT]) has been recognized as a possible option for value investors after being selected through a "Decent Value" screening method. This approach looks for stocks with good v... Full story

Yahoo Finance • 4 months ago

Earnings call transcript: Veracyte's Q2 2025 earnings beat expectations, stock falls

Veracyte Inc. reported a significant earnings beat for the second quarter of 2025, with actual earnings per share (EPS) of $0.44 surpassing forecasts of $0.11, marking a 300% surprise. Revenue also exceeded expectations, coming in at $130.... Full story

Yahoo Finance • 4 months ago

Veracyte raises 2025 revenue guidance to $504M as Decipher volumes surge and strategic investments accelerate

Earnings Call Insights: Veracyte, Inc. (VCYT) Q2 2025 MANAGEMENT VIEW * CEO Marc A. Stapley stated that "We delivered 14% revenue growth year-over-year with total revenue of $130 million." He cited testing revenue growth of 14% year-ov... Full story

Yahoo Finance • 4 months ago

Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion

We recently published 10 Shares Explode as Earnings Impress. Veracyte, Inc. (NASDAQ:VCYT) is one of the best-performing stocks on Friday. Veracyte grew its share price by 7.04 percent on Friday to close at $25.25 apiece following announce... Full story

Yahoo Finance • 4 months ago

Cathie Wood's ARK ETF adjusts portfolio, buys ABSCI, sells CRISPR

In the latest trading session, Cathie Wood’s ARK ETFs made several significant transactions as part of their ongoing portfolio adjustments. On Friday, July 25th, 2025, the most substantial trade came from the purchase of 2,248,226 shares o... Full story

Yahoo Finance • 4 months ago

Veracyte Set to Join S&P SmallCap 600

NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners... Full story

Yahoo Finance • 4 months ago

Oversold Conditions For Veracyte (VCYT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 5 months ago

Veracyte Q3 2024 slides: Revenue surges 29%, guidance raised for third time

Introduction & Market Context Veracyte Inc (NASDAQ:VCYT) presented its third quarter 2024 business and financial results on November 6, 2024, showcasing exceptional performance with 29% year-over-year revenue growth. The cancer diagnosti... Full story

Yahoo Finance • 5 months ago

Cathie Wood's ARK ETFs shuffle healthcare and tech stock holdings

Cathie Wood’s ARK ETFs have made their daily trades for Wednesday, June 25th, 2025, with a significant focus on healthcare and technology stocks. The trades included both substantial acquisitions and divestitures, reflecting ARK’s ongoing... Full story

Yahoo Finance • 5 months ago

Cathie Wood's ARK ETF trades Shopify, Toast stock amid tech focus

Cathie Wood’s ARK ETFs have revealed their daily trades for Tuesday, June 24th, 2025, with notable activity in the technology sector. ARK’s most significant trades of the day included purchases of Shopify Inc (NYSE:NASDAQ:SHOP) and Toas... Full story

Yahoo Finance • 5 months ago

Cathie Wood's ARK buys AMD and sells CRCL stock in daily trades

Cathie Wood’s ARK ETFs have disclosed their daily trades for Friday, June 20th, 2025, revealing a series of significant transactions in the tech and biotech sectors. The most substantial move was the sale of shares in Circle Internet Group... Full story

Yahoo Finance • 5 months ago

Cathie Wood's ARK buys BWX stock, sells Adaptive Biotech

Cathie Wood’s ARK ETFs have made their latest round of daily trades for Wednesday, June 18th, 2025, with BWX Technologies Inc (NYSE:BWXT) and Veracyte Inc (NASDAQ:VCYT) topping the buy list, while Adaptive Biotechnologies Corp (NASDAQ:... Full story

Yahoo Finance • 5 months ago

Cathie Wood's ARK ETF adjusts portfolio with key stock trades

Cathie Wood’s ARK ETF published their daily trades for Tuesday, June 17th, 2025, revealing a series of strategic moves in the tech and biotech sectors. The largest dollar-value trade of the day involved a significant sell-off of CIRCLE INT... Full story

Yahoo Finance • last year

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Findings are from ancillary study of phase 3 STAMPEDE trial Data support company’s plan to expand Decipher Prostate test to patients with metastatic disease SOUTH SAN FRANCISCO, Calif., September 15, 2024--(BUSINESS WIRE)--Veracyte, Inc.... Full story

Yahoo Finance • 2 years ago

Is Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?

Key Insights The projected fair value for Veracyte is US$35.05 based on 2 Stage Free Cash Flow to Equity Current share price of US$20.12 suggests Veracyte is potentially 43% undervalued Analyst price target for VCYT is US$30.60 which is 1... Full story

Yahoo Finance • 2 years ago

Q1 2024 Veracyte Inc Earnings Call

Participants Shayla Gorman; Senior Director, Investor Relations; Veracyte Inc Marc Stapley; Chief Executive Officer, Director; Veracyte Inc Rebecca Chambers; Chief Financial Officer; Veracyte Inc Andrew Brackmann; Analyst; William Blai... Full story